Sarcoma / 2018 / Article / Tab 1

Review Article

Addressing the Adult Soft Tissue Sarcoma Microenvironment with Intratumoral Immunotherapy

Table 1

Clinical trials of intratumoral viral vector therapy in soft tissue sarcoma.


TNFerade14Of 13 evaluable patients, 11 (85%) objective or pathological tumor responses (2 CR and 9 PR), 1 SD[60]
ONYX-015 (+mitomycin-C, doxorubicin, cisplatin)6ONYX-015 viral DNA detected in 2 patient biopsies and 5 patient plasma after treatment[61]
Ad5/3-D24-GMCSF152 minor responses, 6 SD, and 4 PD in 12 evaluable patients; median survival time after treatment was 170 days. One patient was alive at 1459 days[62]
HSV17169Four of 5 patients evaluated at day +14 had stable disease by cross-sectional imaging. Three of 7 patients evaluated at day +28 had stable disease, and one of these patients had a decrease in PET standardized uptake values[63]

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.